Johnson & Johnson (JNJ)
Chart Events
Performance Outlook
| Previous Close | 160.65 |
| Open | 160.30 |
| Bid | 160.50 x 1300 |
| Ask | 160.75 x 1400 |
| Day's Range | 159.11 - 161.41 |
| 52 Week Range | 109.16 - 161.95 |
| Volume | 7,427,398 |
| Avg. Volume | 7,373,750 |
| Market Cap | 421.996B |
| Beta (5Y Monthly) | 0.70 |
| PE Ratio (TTM) | 25.20 |
| EPS (TTM) | 6.36 |
| Earnings Date | Jan 26, 2021 |
| Forward Dividend & Yield | 4.04 (2.52%) |
| Ex-Dividend Date | Feb 22, 2021 |
| 1y Target Est | 167.59 |
Fair Value
Related Research
ReutersCOVID SCIENCE-Progress reported on one-dose J&J vaccine; COVID-19 reinfections seen as rare
The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus. An experimental COVID-19 vaccine from Johnson & Johnson produced protective antibodies against the novel coronavirus in 90% of 805 volunteers by 29 days, and that increased to 100% by day 57, according to data from an ongoing mid-stage study. To be approved by regulators, the J&J vaccine must show efficacy as reflected by a lower risk of infections and severe disease in study participants who receive it compared to those who do not.
- Investor's Business Daily
Is Novavax Stock A Buy As Pressure Mounts For A Covid-19 Vaccine?
Novavax is making a play for a coronavirus vaccine, vs. giants like Pfizer, and other rivals like Moderna. But NVAX stock has been volatile. Is Novavax stock a buy right now?
- Yahoo Finance
Coronavirus update: Biden calls for 100 million vaccinations, $121 billion for health care to fight COVID-19
President-elect Joe Biden released a $1.9 trillion COVID-19 response plan on Thursday evening, setting goals for his first 100 days in office, including a call for 100 million vaccinations by then.
